E
Enrico Cortesi
Researcher at Sapienza University of Rome
Publications - 258
Citations - 10879
Enrico Cortesi is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 37, co-authored 229 publications receiving 9438 citations. Previous affiliations of Enrico Cortesi include Policlinico Umberto I & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis,Chiara Cremolini,Gianluca Masi,Sara Lonardi,Vittorina Zagonel,Lisa Salvatore,Enrico Cortesi,Gianluca Tomasello,Monica Ronzoni,Rosella Spadi,Alberto Zaniboni,Giuseppe Tonini,Angela Buonadonna,Domenico Amoroso,Silvana Chiara,Chiara Carlomagno,Corrado Boni,Giacomo Allegrini,Luca Boni,Alfredo Falcone +19 more
TL;DR: FOLFOXIRI plus bevacizumab, as compared with FOLFIRI plus was improved the outcome in patients with metastatic colorectal cancer and increased the incidence of some adverse events.
Journal ArticleDOI
Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients
Cristina Raimondi,Angela Gradilone,Giuseppe Naso,Bruno Vincenzi,Arianna Petracca,Chiara Nicolazzo,Antonella Palazzo,R. Saltarelli,Franco Spremberg,Enrico Cortesi,Paola Gazzaniga +10 more
TL;DR: The detection of cells in mesenchymal transition, retaining EMT and stemness features, may contribute to discover additional therapeutic targets useful to eradicate micrometastatic disease in breast cancer.
Journal ArticleDOI
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
Gianluca Masi,Fotios Loupakis,Lisa Salvatore,Lorenzo Fornaro,Chiara Cremolini,Samanta Cupini,A. Ciarlo,Francesca Del Monte,Enrico Cortesi,Domenico Amoroso,Cristina Granetto,Gabriella Fontanini,Elisa Sensi,Cristiana Lupi,Michele Andreuccetti,Alfredo Falcone +15 more
TL;DR: The primary endpoint was progression-free survival at 10 months from study entry in the intention-to-treat population, and treatment achieved promising results in terms of PFS.
Journal ArticleDOI
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
Chiara Nicolazzo,Cristina Raimondi,M. Mancini,Salvatore Caponnetto,Angela Gradilone,Orietta Gandini,Maria Mastromartino,Gabriella Del Bene,Alessandra Anna Prete,Flavia Longo,Enrico Cortesi,Paola Gazzaniga +11 more
TL;DR: The persistence of PD-L1(+) CTCs might mirror a mechanism of therapy escape, and patients could be dichotomized into two groups based PD- L1 expression on C TCs, which suggests that the persistence ofPD-L2 negative CTCS all obtained a clinical benefit, while patients with PD-CTCs all experienced progressive disease.